LivaNova PLC (LIVN): Results of Operations and Financial Condition
LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev
How this was made
The 30-second read
Why it matters
The guidance raise and disclosed oxygenator component supply agreement are likely to drive estimate revisions and near-term sentiment, while the lowered adjusted free cash flow range and reliance on non-GAAP metrics add uncertainty around cash conversion.
Market read
Traders can update 2026 revenue, adjusted EPS, and cash-flow expectations immediately based on the raised guidance ranges and the newly disclosed supply-chain and tax catalysts.
What to watch
The filing highlights non-GAAP measures and a discrete tax benefit; traders may discount sustainability of the tax impact and scrutinize whether cash flow headwinds persist beyond 2026.
Background
This is an SEC Form 8-K (Item 2.02) with LivaNova’s Q2 2026 results and updated full-year 2026 guidance, plus operational, tax, and leadership updates.
Ticker impact
LivaNova raised full-year 2026 revenue growth to 8% to 9% and adjusted EPS to $4.30 to $4.40 after reporting Q2 results.
Likely upward bias for near-term trading as the guidance increase and supply-chain deal support higher confidence in 2026 estimates.
The filing discloses multiple fresh, decision-relevant items: Q2 revenue and EPS figures, raised 2026 guidance ranges, a long-term Thermo Fisher oxygenator component agreement, and a discrete €81.8 million tax benefit from Agenzia delle Entrate.
Market effects
Medical technology and cardiopulmonary supply-chain confidence may improve for peers with similar oxygenator component dependencies, though the disclosure is company-specific.
Italian tax authority ruling reduces jurisdiction-specific overhang for LIVN; limited direct spillover to other regions.
Thermo Fisher supply agreement could reinforce broader oxygenator manufacturing capacity expectations, but impact is primarily through LIVN’s guidance.
Counterpoint
Raised guidance comes with a lowered adjusted free cash flow range ($140M to $160M vs $160M to $180M prior), implying margin or cash conversion tradeoffs from capacity and IT investments.
Key entities
- public_companyLivaNova PLC
Nasdaq-listed medical technology company reporting Q2 2026 results and raising full-year 2026 guidance.
- public_companyThermo Fisher Scientific
Entered into a long-term agreement with LivaNova to strengthen oxygenator component supply.
- government_agencyAgenzia delle Entrate
Italian tax authority issuing a favorable ruling recognizing a discrete €81.8 million tax benefit.
- personJette Nygaard-Anderson
Appointed to LivaNova’s Board and Nominating and Corporate Governance Committee effective June 10.
- personStefano Folli
Appointed President, Cardiopulmonary effective August 1.